Ocugen, Inc. (OCGN) announced an update on the safety and efficacy of its Phase 1/2 clinical trial for OCU400, aimed at treating retinitis pigmentosa, a condition affecting children and adults.
OCU400, a gene therapy that leverages the NR2E3 nuclear hormone receptor gene, has shown promising results in improving low-light visual acuity and demonstrating effectiveness across various genetic mutations.
The company also noted that the Phase 3 OCU400 liMeliGhT clinical trial remains on schedule, with a Biologics License Application (BLA) submission expected in the first half of 2026.
In pre-market trading, Ocugen's stock has risen by 1.58%, currently priced at $0.799 on the Nasdaq.
